ArticleFrontiers in oncology2025
Case Report: The double-edged sword: cytokine release syndrome and rapid tumor response in a patient treated with amivantamab and chemotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report a well-documented case of cytokine release syndrome (CRS) following the first cycle of amivantamab combined with chemotherapy in a patient with osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC), highlighting its diagnosis, management, and association with a rapid antitumor response. Case summary: A 72-year-old man with metastatic lung adenocarcinoma (epidermal growth factor receptor (EGFR) exon 19 del) progressing on osimertinib initiated treatment with amivantamab, pemetrexed, and carboplatin. Five days post-infusion, he developed a persistent fever unresponsive to broad-spectrum antibiotics. Infection was rigorously excluded based on normal procalcitonin, undetectable endotoxin, and negative cultures. In contrast, inflammatory markers were elevated (peak CRP (C-reactive protein) 16.6 mg/dL), and cytokine profiling revealed significant elevations in IL-6 (interleukin-6) (107 pg/mL), sIL-2R (soluble interleukin-2 receptor), TNF-α (tumor necrosis factor-alpha), and IL-10, accompanied by profound lymphopenia. A computed tomography (CT) scan demonstrated a significant tumor reduction. A diagnosis of grade 1 CRS (by ASTCT (American Society for Transplantation and Cellular Therapy) criteria) was made. The fever and inflammatory markers resolved with supportive care. Findings: This case provides comprehensive clinical and serological evidence of amivantamab-chemotherapy-induced CRS. The temporal association between the robust cytokine surge, characteristic of T-cell activation, and the observed rapid tumor regression suggests that the same immunologic mechanism likely underpinned both the efficacy and the toxicity. Conclusion: CRS is an important adverse event associated with amivantamab-based combination therapy in solid tumors. Early recognition, based on clinical suspicion and characteristic cytokine profiles, and differentiation from infection are crucial. The concurrent rapid tumor response indicates that effective immune activation drives both toxicity and efficacy, underscoring the need for optimal management strategies to mitigate CRS without compromising antitumor activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.